HEPA · Hepion Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | $0 | $0 | $0 | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $445.5K | $11.85M | $35.64M | $33.27M | $20.40M | $12.00M |
| SG&A | $3.32M | $7.50M | $9.62M | $10.35M | $10.01M | $8.15M |
| Total Operating Expenses | $4.16M | $19.35M | $48.45M | $45.49M | $30.40M | $20.15M |
| D&A | - | $30.8K | $67.1K | $77.5K | $86.1K | $34.5K |
| Operating Income | ($4.16M) | ($19.35M) | ($48.45M) | ($45.49M) | ($30.40M) | ($20.15M) |
| Interest Expense | - | - | $9.5K | $10.2K | $8.9K | $31.2K |
| Income Tax | - | ($2.97M) | ($409.0K) | ($2.88M) | $0 | $30.6K |
| Net Income | ($8.28M) | ($13.19M) | ($48.93M) | ($42.20M) | ($32.72M) | ($20.35M) |
| EPS - Basic | ($0.88) | ($107.35) | ($616.00) | ($590.00) | ($2100.00) | - |
| EPS - Diluted | ($0.88) | ($107.35) | ($616.00) | ($590.00) | ($2100.00) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.83M | $406.4K | $14.79M | $51.19M | $91.35M | $40.73M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $167.8K | $220.2K | $2.35M | $2.67M | $2.45M | $3.72M |
| Current Assets | $3.07M | $1.61M | $17.49M | $56.50M | $97.45M | $42.63M |
| Total Assets | $3.07M | $1.61M | $18.09M | $60.24M | $103.55M | $48.65M |
| Current Liabilities | $299.4K | $3.14M | $5.29M | $7.89M | $8.21M | $4.66M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $402.4K | $3.48M | $10.81M | $10.39M | $10.56M | $8.12M |
| Stockholders' Equity | $2.67M | ($1.86M) | $7.28M | $49.86M | $93.00M | $40.52M |
| Retained Earnings | ($246.10M) | ($237.82M) | ($224.63M) | ($175.70M) | ($133.50M) | ($104.11M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.27M) | ($18.22M) | ($40.89M) | ($34.96M) | ($31.22M) | ($16.17M) |
| Investing Cash Flow | ($132.1K) | ($600.0K) | ($14.3K) | ($14.1K) | ($130.4K) | ($85.8K) |
| Financing Cash Flow | $4.83M | $4.35M | $4.49M | ($5.14M) | $81.98M | $43.05M |
| CapEx | - | - | $14.3K | $16.3K | $130.4K | $88.0K |
| Free Cash Flow | - | - | ($40.90M) | ($34.98M) | ($31.35M) | ($16.25M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | 0.84 | 0.83 | 0.96 | 0.80 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -269.6% | -817.5% | -270.4% | -70.0% | -31.6% | -41.8% |
| Return on equity | -310.3% | 708.0% | -672.0% | -84.6% | -35.2% | -50.2% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 10.25 | 0.51 | 3.31 | 7.16 | 11.88 | 9.15 |
| Quick ratio | 10.25 | 0.51 | 3.31 | 7.16 | 11.88 | 9.15 |
| Cash ratio | 6.11 | 0.13 | 2.80 | 6.49 | 11.13 | 8.74 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | -5118.6x | -4475.5x | -3431.9x | -645.1x |
| Equity multiplier | 1.15 | -0.87 | 2.49 | 1.21 | 1.11 | 1.20 |
| Liabilities / Assets | 0.13 | 2.15 | 0.60 | 0.17 | 0.10 | 0.17 |
| Efficiency | ||||||
| Asset turnover | - | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 0.2x | - | 88.4x | 458.7x | 118.6x | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 78.5% | 60.1% | -6.5% | -49.6% | -50.9% | -159.3% |
| Net income growth (YoY) | 37.3% | 73.0% | -15.9% | -29.0% | -60.8% | -202.9% |
| EPS growth (YoY) | 99.2% | 82.6% | -4.4% | 71.9% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -16.9% | -11.6% | -92.9% | -113.4% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | -85.4% | -46.4% | 129.5% | 150.3% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Hepion Pharmaceuticals against the 5 most active filers in the same SIC group.